One drug, one FDA date
- Mineralys has no product revenue today, so the story depends on lorundrostat reaching the market.
- The FDA accepted the hypertension NDA and set a PDUFA target action date of December 22, 2026.
- Positive hypertension data lowered clinical risk, but approval is still not guaranteed.
- The CKD study met its endpoints, giving lorundrostat a possible second path if regulators agree.
- The OSA trial missed its primary endpoint, which cuts off a near-term expansion idea.
A hard FDA clock
Mineralys is now a regulatory story with a clear date. The company submitted its NDA, which is the formal drug approval application, for lorundrostat in hypertension in December 2025. The FDA accepted it and set a PDUFA target action date of December 22, 2026.
The bull case is simple. Lorundrostat has already shown positive data in uncontrolled and resistant hypertension. It also produced positive Phase 2 results in chronic kidney disease, or CKD, where kidney damage and high blood pressure often overlap. If approved, Mineralys could move from a no-revenue biotech into a commercial launch story.
The bear case is also clear. Mineralys still owns one main drug and has not launched a product before. FDA acceptance of the NDA is not the same as approval. The failed Phase 2 OSA trial also shows that lorundrostat may not work across every disease the company tests.
The next big watch item is the FDA decision. Before then, investors should look for launch planning, payer strategy, and any update on whether CKD can move toward a label expansion or needs a larger trial.
Cash now, launch later
Mineralys does not make money from drug sales today. It spends cash to run studies, prepare filings, and build for a possible launch. Its value comes from the chance that lorundrostat becomes an approved medicine.
Lorundrostat was in-licensed from Mitsubishi Tanabe Pharmaceutical Company. That means Mineralys controls development and possible commercialization, but it may owe milestone payments and future royalties if the drug succeeds.
The company has funded itself through its IPO and later equity financings. That is normal for a clinical-stage biotech, but it matters for shareholders. A full launch can cost a lot, so future stock sales could dilute existing owners.
Commercial success will depend on more than FDA approval. Doctors must prescribe the drug, insurers must cover it, and pricing must make sense in a crowded high blood pressure market.
Lorundrostat, by use case
Lorundrostat for uncontrolled hypertension
This is the lead use case and the center of the NDA. The FDA target action date is December 22, 2026.
Lorundrostat for resistant hypertension
This is part of the same high blood pressure filing path. It targets patients whose blood pressure stays high even with other medicines.
Lorundrostat for chronic kidney disease
The Phase 2 Explore-CKD trial met its endpoints, including blood pressure and albuminuria, a marker of kidney damage. The open question is whether regulators need a dedicated Phase 3 trial.
Lorundrostat for obstructive sleep apnea
The Phase 2 Explore-OSA trial missed its primary endpoint. This makes OSA a weak near-term value driver, even though blood pressure changes and safety were favorable.
Other cardiorenal uses
Mineralys may look for more diseases tied to aldosterone, blood pressure, heart, or kidney risk. After the OSA miss, investors need proof before giving much value to new ideas.
No sales mix yet
Mineralys reported one operating segment and no commercial product revenue in its 2025 annual filing and Q1 2026 update. The split below is a practical view of the business today: all current effort is development, while commercial products are not yet active.
What can break
FDA rejects or delays lorundrostat
High impact · Medium oddsThe NDA has been accepted, but the drug is not approved yet. The FDA could ask for more safety data, more analysis, labeling limits, or a new study. Since lorundrostat is the main asset, a negative decision would hit the whole company.
One-drug concentration
High impact · High oddsMineralys is built around lorundrostat. If the drug fails in hypertension or gets a narrow label, there is no approved second product to offset the damage. The OSA miss already showed the risk of leaning on one molecule for many uses.
CKD path needs more trials
Medium impact · Medium oddsExplore-CKD was positive, but it was Phase 2. The FDA may decide that Mineralys needs a dedicated Phase 3 trial before CKD can become a formal label indication. That would add time, cost, and execution risk.
Launch costs dilute shareholders
Medium impact · Medium oddsA commercial launch needs sales staff, medical education, payer work, and inventory. Mineralys is well funded through the PDUFA date, but a broader launch may still require more capital. If that money comes from selling stock, current shareholders own a smaller piece.
Pricing and coverage fall short
High impact · Medium oddsHigh blood pressure is a large market, but many older medicines are cheap. Lorundrostat must win a clear place in treatment for insurers and doctors. Approval alone may not equal strong sales.
In one breath
What does Mineralys Therapeutics do?
Mineralys is developing lorundrostat, an oral drug that blocks aldosterone production. Aldosterone is a hormone that can raise blood pressure and affect heart and kidney health.
When is the key FDA date for MLYS?
The FDA set a PDUFA target action date of December 22, 2026 for lorundrostat in hypertension. That is the main near-term catalyst for the stock.
Does Mineralys have revenue?
No. Mineralys is still clinical stage and has not commercialized a product, so it has no product revenue today.
Why did the OSA trial matter?
OSA, or obstructive sleep apnea, was a possible expansion area for lorundrostat. The Phase 2 trial missed its primary endpoint, so it is no longer a near-term driver of the investment case.